Anti‐IL17 Secukinumab in hidradenitis suppurativa: A long‐term drug survival analysis
Gabriele Roccuzzo,
Federica Repetto,
Silvia Giordano
et al.
Abstract:Real‐world data on the long‐term effectiveness of the anti‐IL17 agent secukinumab in treating moderate‐to‐severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 patients with moderate–severe HS received five weekly subcutaneous injections followed by maintenance doses every 4 weeks. Primary outcomes included HiSCR, IHS4 reduction, and DLQI measures assessed at 12‐week intervals. The median secukinumab drug survival was 16.0 months (range 3–51), with a 56.5% maximal response rate at 6 months and dr… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.